NeOnc Technologies (NTHI)
Market Price (8/9/2026): $3.59 | Market Cap: $83.6 MilSector: Health Care | Industry: Biotechnology
NeOnc Technologies (NTHI)
Market Price (8/9/2026): $3.59Market Cap: $83.6 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. | Weak multi-year price returns2Y Excs Rtn is -116%, 3Y Excs Rtn is -143% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -33 Mil Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -52% Key risksNTHI key risks include [1] poor financial health with a high risk of bankruptcy, Show more. |
| Megatrend and thematic driversMegatrends include Aging Population & Chronic Disease, and Precision Medicine. Themes include Oncology Treatments, Targeted Therapies, Show more. |
| Weak multi-year price returns2Y Excs Rtn is -116%, 3Y Excs Rtn is -143% |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -33 Mil |
| Weak revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is null, Rev Chg QQuarterly Revenue Change % is null |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -52% |
| Key risksNTHI key risks include [1] poor financial health with a high risk of bankruptcy, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 8/1/2026
NeOnc Technologies (NTHI) stock has lost about 20% since 4/30/2026 because of the following key factors:
1. Q1 2026 Earnings Miss and Ongoing Financial Health Concerns. On May 18, 2026, NeOnc Technologies reported fiscal Q1 2026 losses of $(0.38) per share, significantly missing the analyst consensus estimate of $(0.17) by 123.53%. This disappointing quarterly performance compounded existing concerns about the company's financial health, as its fiscal year 2025 revenue had already decreased by 51.82% to $39,990, alongside a 422.3% increase in losses to -$62.15 million, leading auditors to issue a "going concern" risk due to recurring losses and low cash reserves.
2. Regulatory Feedback and Pipeline Development Uncertainty for NEO212. On July 15, 2026, NeOnc Technologies announced it received written feedback from the FDA regarding NEO212 Chemistry, Manufacturing, and Controls (CMC) development and capsule-to-tablet transition. Although described as providing detailed requirements, the market reacted negatively, with the stock price decreasing by 3.80% on that day. This suggests investor apprehension regarding potential additional developmental hurdles or delays associated with a key pipeline asset, contributing to the stock's downward trend.
Show more
NeOnc Technologies (NTHI) stock has lost about 20% since 4/30/2026 because of the following key factors:
1. Q1 2026 Earnings Miss and Ongoing Financial Health Concerns. On May 18, 2026, NeOnc Technologies reported fiscal Q1 2026 losses of $(0.38) per share, significantly missing the analyst consensus estimate of $(0.17) by 123.53%. This disappointing quarterly performance compounded existing concerns about the company's financial health, as its fiscal year 2025 revenue had already decreased by 51.82% to $39,990, alongside a 422.3% increase in losses to -$62.15 million, leading auditors to issue a "going concern" risk due to recurring losses and low cash reserves.
2. Regulatory Feedback and Pipeline Development Uncertainty for NEO212. On July 15, 2026, NeOnc Technologies announced it received written feedback from the FDA regarding NEO212 Chemistry, Manufacturing, and Controls (CMC) development and capsule-to-tablet transition. Although described as providing detailed requirements, the market reacted negatively, with the stock price decreasing by 3.80% on that day. This suggests investor apprehension regarding potential additional developmental hurdles or delays associated with a key pipeline asset, contributing to the stock's downward trend.
Show more
Updated on 8/1/2026
NeOnc Technologies (NTHI) stock has lost about 20% since 4/30/2026 because of the following key factors:
1. Q1 2026 Earnings Miss and Ongoing Financial Health Concerns. On May 18, 2026, NeOnc Technologies reported fiscal Q1 2026 losses of $(0.38) per share, significantly missing the analyst consensus estimate of $(0.17) by 123.53%. This disappointing quarterly performance compounded existing concerns about the company's financial health, as its fiscal year 2025 revenue had already decreased by 51.82% to $39,990, alongside a 422.3% increase in losses to -$62.15 million, leading auditors to issue a "going concern" risk due to recurring losses and low cash reserves.
2. Regulatory Feedback and Pipeline Development Uncertainty for NEO212. On July 15, 2026, NeOnc Technologies announced it received written feedback from the FDA regarding NEO212 Chemistry, Manufacturing, and Controls (CMC) development and capsule-to-tablet transition. Although described as providing detailed requirements, the market reacted negatively, with the stock price decreasing by 3.80% on that day. This suggests investor apprehension regarding potential additional developmental hurdles or delays associated with a key pipeline asset, contributing to the stock's downward trend.
3. Lack of Sustained Positive Impact from UAE Approvals and Anticipation of Critical Data Readouts. While NeOnc Technologies received positive news with UAE Investigational New Drug (IND) approvals for NEO212 on June 16, 2026, (leading to a 14.86% stock increase) and for NEO100 on June 23, 2026, (followed by a 4.50% stock decrease), these did not translate into a sustained upward trend for the stock. This indicates that investors are keenly focused on the anticipated interim data readout for NEO100 Phase 2a, expected around August 2026, and a Type B End-of-Phase FDA meeting for NEO212. The approaching critical milestones, without confirmed positive outcomes, contribute to investor caution and volatility.
4. Cautious Investor Sentiment Towards Early-Stage Biotech. Although the broader biotech sector experienced an upward trend in funding during fiscal Q2 2026, raising $34.3 billion, there was a notable decline in new company financing (seed and Series A rounds) to its lowest level in years. As a clinical-stage biopharmaceutical company with no product revenue, NeOnc Technologies is particularly susceptible to this cautious sentiment towards early-stage investments, despite general improvements in the broader biopharma market sentiment.
Show less
NeOnc Technologies (NTHI) stock has lost about 20% since 4/30/2026 because of the following key factors:
1. Q1 2026 Earnings Miss and Ongoing Financial Health Concerns. On May 18, 2026, NeOnc Technologies reported fiscal Q1 2026 losses of $(0.38) per share, significantly missing the analyst consensus estimate of $(0.17) by 123.53%. This disappointing quarterly performance compounded existing concerns about the company's financial health, as its fiscal year 2025 revenue had already decreased by 51.82% to $39,990, alongside a 422.3% increase in losses to -$62.15 million, leading auditors to issue a "going concern" risk due to recurring losses and low cash reserves.
2. Regulatory Feedback and Pipeline Development Uncertainty for NEO212. On July 15, 2026, NeOnc Technologies announced it received written feedback from the FDA regarding NEO212 Chemistry, Manufacturing, and Controls (CMC) development and capsule-to-tablet transition. Although described as providing detailed requirements, the market reacted negatively, with the stock price decreasing by 3.80% on that day. This suggests investor apprehension regarding potential additional developmental hurdles or delays associated with a key pipeline asset, contributing to the stock's downward trend.
3. Lack of Sustained Positive Impact from UAE Approvals and Anticipation of Critical Data Readouts. While NeOnc Technologies received positive news with UAE Investigational New Drug (IND) approvals for NEO212 on June 16, 2026, (leading to a 14.86% stock increase) and for NEO100 on June 23, 2026, (followed by a 4.50% stock decrease), these did not translate into a sustained upward trend for the stock. This indicates that investors are keenly focused on the anticipated interim data readout for NEO100 Phase 2a, expected around August 2026, and a Type B End-of-Phase FDA meeting for NEO212. The approaching critical milestones, without confirmed positive outcomes, contribute to investor caution and volatility.
4. Cautious Investor Sentiment Towards Early-Stage Biotech. Although the broader biotech sector experienced an upward trend in funding during fiscal Q2 2026, raising $34.3 billion, there was a notable decline in new company financing (seed and Series A rounds) to its lowest level in years. As a clinical-stage biopharmaceutical company with no product revenue, NeOnc Technologies is particularly susceptible to this cautious sentiment towards early-stage investments, despite general improvements in the broader biopharma market sentiment.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -20.8% change in NTHI stock from 4/30/2026 to 8/8/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 4302026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.42 | 3.50 | -20.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | |
| P/S Multiple | 2,346.8 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 21 | 23 | -8.8% |
| Cumulative Contribution | 0.0% |
Market Drivers
4/30/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| NTHI | -20.8% | |
| Market (SPY) | 7.6% | 0.7% |
| Sector (XLV) | 13.5% | 2.8% |
Fundamental Drivers
The -62.2% change in NTHI stock from 1/31/2026 to 8/8/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 1312026 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 9.27 | 3.50 | -62.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | |
| P/S Multiple | 2,968.7 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 19 | 23 | -17.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2026 to 8/8/2026| Return | Correlation | |
|---|---|---|
| NTHI | -62.2% | |
| Market (SPY) | 12.1% | 11.1% |
| Sector (XLV) | 7.5% | 7.9% |
Fundamental Drivers
The -28.6% change in NTHI stock from 7/31/2025 to 8/8/2026 was primarily driven by a null change in the company's Total Revenues ($ Mil).| (LTM values as of) | 7312025 | 8082026 | Change |
|---|---|---|---|
| Stock Price ($) | 4.90 | 3.50 | -28.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | |
| P/S Multiple | 1,458.0 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 19 | 23 | -19.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 8/8/2026| Return | Correlation | |
|---|---|---|
| NTHI | -28.6% | |
| Market (SPY) | 23.4% | 21.0% |
| Sector (XLV) | 28.7% | 10.4% |
Fundamental Drivers
nullnull
Market Drivers
7/31/2023 to 8/8/2026| Return | Correlation | |
|---|---|---|
| NTHI | ||
| Market (SPY) | 74.9% | -2.3% |
| Sector (XLV) | 29.3% | -4.8% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| NTHI Return | - | - | - | - | -32% | -58% | -71% |
| Peers Return | -20% | -26% | -32% | -18% | -37% | 79% | -63% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 105% |
Monthly Win Rates [3] | |||||||
| NTHI Win Rate | - | - | - | - | 60% | 50% | |
| Peers Win Rate | 33% | 40% | 42% | 45% | 38% | 55% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| NTHI Max Drawdown | - | - | - | - | - | -70% | |
| Peers Max Drawdown | -64% | -60% | -70% | -60% | -62% | -37% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: NVCR, DNLI, CLDX, IBRX, CNSP.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/7/2026 (YTD)
How Low Can It Go
NTHI has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -11.7% | -18.8% |
| % Gain to Breakeven | 13.3% | 23.1% |
| Time to Breakeven | 142 days | 79 days |
| 2022 Inflation Shock & Fed Tightening | ||
| % Loss | -13.8% | -24.5% |
| % Gain to Breakeven | 15.9% | 32.4% |
| Time to Breakeven | 166 days | 427 days |
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -15.0% | -19.2% |
| % Gain to Breakeven | 17.6% | 23.8% |
| Time to Breakeven | 191 days | 105 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -15.9% | -12.2% |
| % Gain to Breakeven | 18.9% | 13.9% |
| Time to Breakeven | 165 days | 62 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -15.8% | -17.9% |
| % Gain to Breakeven | 18.8% | 21.8% |
| Time to Breakeven | 153 days | 123 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
NTHI has limited trading history. Below is the Health Care sector ETF (XLV) in its place.
| Event | XLV | S&P 500 |
|---|---|---|
| 2020 COVID-19 Crash | ||
| % Loss | -27.9% | -33.7% |
| % Gain to Breakeven | 38.8% | 50.9% |
| Time to Breakeven | 77 days | 140 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -37.9% | -53.4% |
| % Gain to Breakeven | 61.1% | 114.4% |
| Time to Breakeven | 767 days | 1085 days |
In The Past
State Street Health Care Select Sector SPDR ETF's stock fell -11.7% during the 2025 US Tariff Shock. Such a loss loss requires a 13.3% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About NeOnc Technologies (NTHI)
NeOnc Technologies (NTHI) is a clinical-stage biopharmaceutical company focused on developing novel drugs and drug delivery methods to treat aggressive cancers located in the brain, known as intracranial malignancies. The company aims to overcome the significant challenge of the blood-brain barrier, which typically prevents most therapeutic agents from effectively reaching brain tumors. NeOnc targets both primary brain cancers, such as glioblastoma, and secondary brain cancers that have metastasized from other parts of the body, including melanoma, breast, and lung cancers.
The company's lead product, NEO100, is a purified form of perillyl acid (POH) administered via an intranasal route. NEO100 is currently in Phase IIa clinical trials for patients with recurrent high-grade gliomas (specifically IDH1,2 mutant Grade III and IV astrocytomas) and for malignant skull-based meningioma, with a projected readout for the glioma trial by the end of 2024. Beyond oncology, NEO100 is also being investigated as a drug delivery vehicle, with a Phase I clinical trial planned to explore its combination with levodopa for treating Parkinson's disease.
NeOnc's second key product in development is NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol. NEO212 has completed preclinical testing and received IND approval, with an oral Phase I/II trial initiated in late 2023 for patients with primary brain tumors (malignant gliomas) and secondary brain metastases. As a clinical-stage company, NeOnc currently has no commercial products approved for sale and is focused solely on advancing its drug candidates through clinical trials to obtain regulatory approvals.
AI Analysis | Feedback
1. It's like a startup trying to be the next Biogen for brain disorders, but specifically pioneering intranasal drug delivery to tackle difficult conditions like brain cancer and Parkinson's.
2. Imagine a company similar to an early-stage Moderna or BioNTech, but instead of mRNA vaccines, they're developing nasal spray-delivered drugs to treat challenging brain cancers and Parkinson's disease.
AI Analysis | Feedback
Major Products of NeOnc Technologies (NTHI):
- NEO100: A purified form of perillyl acid (POH) administered intranasally for treating recurrent malignant gliomas, malignant skull-based meningiomas, and as a drug delivery vehicle for other therapies like levodopa for Parkinson's disease.
- NEO212: A covalently conjugated molecule combining temozolomide with perillyl alcohol, currently in a Phase I/II trial for oral administration to treat primary and secondary brain tumors, with future development for intranasal application.
AI Analysis | Feedback
```html
Based on the provided background information, NeOnc Technologies (NTHI) is a clinical-stage biopharmaceutical company. The company is currently focused on developing novel drug delivery methods and drug candidates for intracranial malignancies. Their lead products, NEO100 and NEO212, are in various stages of clinical trials (Phase I, Phase IIa) or preclinical development.
The company explicitly states:
- "Currently, none of our product candidates have been approved for sale in the United States or elsewhere."
- "We have no commercial products nor do we have a sales or marketing infrastructure."
Therefore, NeOnc Technologies does not currently have any major customers, as it does not yet have any approved or commercialized products available for sale to other companies or individuals.
```AI Analysis | Feedback
null
AI Analysis | Feedback
Amir F. Heshmatpour, Chief Executive Officer, Executive Chairman, and President
Amir F. Heshmatpour is the Executive Chairman and President of NeOnc Technologies Holdings, Inc. where he drives the company's mission to transform the treatment of brain cancers. He has over 25 years of executive and board leadership experience. In 2005, he founded AFH Holding & Advisory LLC, his single-family office, through which he has led more than $6 billion in transactions across multiple industries, with a focus on biotech and healthcare. He acquired NeOnc in 2023 and assumed the presidency in 2025, and was appointed CEO in November 2025. Previously, he founded and served as Chairman and CEO of Metrophone Telecommunications, which completed 17 acquisitions and grew annual revenues to over $100 million.
Keithly Garnett, Chief Financial Officer
Keithly Garnett serves as the Chief Financial Officer for NeOnc Technologies Holdings, Inc. He directly owns a significant number of shares in the company and indirectly holds additional shares through HCWG LLC, where he is a beneficial owner.
Dr. Thomas C. Chen, MD, PhD, Founder, Chief Medical Officer, and Chief Scientific Officer
Dr. Thomas Chen is the founder of NeOnc Technologies. He transitioned from the CEO role to focus exclusively on his positions as Chief Medical Officer and Chief Scientific Officer, and remains a member of the Board of Directors. This transition allows him to dedicate his full attention to accelerating clinical trials and driving the scientific advancements of NeOnc's drug candidates.
Dr. Josh Neman, PhD, Chief Clinical Officer
Dr. Josh Neman is the Chief Clinical Officer at NeOnc Technologies Holdings, Inc.
David Choi, Chief Accounting Officer
David Choi was appointed as Chief Accounting Officer, effective March 12, 2026. In this role, he is responsible for overseeing the company's accounting, financial reporting, internal controls, and corporate governance functions. Mr. Choi is a CPA with over a decade of public-company accounting and controls experience from previous roles at Blythe Global Advisors, Grant Thornton, and Ernst & Young.
Amir F. Heshmatpour is the Executive Chairman and President of NeOnc Technologies Holdings, Inc. where he drives the company's mission to transform the treatment of brain cancers. He has over 25 years of executive and board leadership experience. In 2005, he founded AFH Holding & Advisory LLC, his single-family office, through which he has led more than $6 billion in transactions across multiple industries, with a focus on biotech and healthcare. He acquired NeOnc in 2023 and assumed the presidency in 2025, and was appointed CEO in November 2025. Previously, he founded and served as Chairman and CEO of Metrophone Telecommunications, which completed 17 acquisitions and grew annual revenues to over $100 million.
Keithly Garnett, Chief Financial Officer
Keithly Garnett serves as the Chief Financial Officer for NeOnc Technologies Holdings, Inc. He directly owns a significant number of shares in the company and indirectly holds additional shares through HCWG LLC, where he is a beneficial owner.
Dr. Thomas C. Chen, MD, PhD, Founder, Chief Medical Officer, and Chief Scientific Officer
Dr. Thomas Chen is the founder of NeOnc Technologies. He transitioned from the CEO role to focus exclusively on his positions as Chief Medical Officer and Chief Scientific Officer, and remains a member of the Board of Directors. This transition allows him to dedicate his full attention to accelerating clinical trials and driving the scientific advancements of NeOnc's drug candidates.
Dr. Josh Neman, PhD, Chief Clinical Officer
Dr. Josh Neman is the Chief Clinical Officer at NeOnc Technologies Holdings, Inc.
David Choi, Chief Accounting Officer
David Choi was appointed as Chief Accounting Officer, effective March 12, 2026. In this role, he is responsible for overseeing the company's accounting, financial reporting, internal controls, and corporate governance functions. Mr. Choi is a CPA with over a decade of public-company accounting and controls experience from previous roles at Blythe Global Advisors, Grant Thornton, and Ernst & Young.
AI Analysis | Feedback
Key Risks to NeOnc Technologies (NTHI)
- Clinical Trial Failure and Regulatory Approval Risk: NeOnc Technologies is a clinical-stage biopharmaceutical company with no currently approved products for sale. The success of the company is entirely dependent on the successful completion of ongoing and planned clinical trials (e.g., Phase IIa for NEO100, Phase I/II for NEO212, planned Phase I for intranasal NEO100 with levodopa) and obtaining regulatory approvals from agencies like the FDA. The background explicitly states that without successful clinical trials and regulatory approvals, the company cannot market and sell its products.
- Commercialization and Market Entry Risk: Even upon successful regulatory approval, NeOnc Technologies faces significant risks in commercializing its products. The company currently has no commercial products and lacks a sales or marketing infrastructure. Building this infrastructure, establishing market presence, and competing effectively in the specialized and challenging brain cancer treatment market will be a substantial undertaking.
- Patient Enrollment and Trial Execution Risk: The company has experienced challenges and made adjustments regarding patient enrollment for its NEO100 trials, specifically related to the limited population of IDH1,2 mutant Grade IV astrocytoma patients, which necessitated expanding the trial to include Grade III IDH1,2 mutant astrocytomas. While this adjustment aims to expedite the trial process, it highlights the inherent difficulties and potential delays associated with recruiting specific patient populations for specialized clinical trials, which can impact timelines and resource allocation.
AI Analysis | Feedback
null
AI Analysis | Feedback
null
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for NeOnc Technologies (NTHI) over the next 2-3 years:
- Accelerated Clinical Development and Expanded Patient Population for NEO100 in High-Grade Astrocytomas: The inclusion of recurrent Grade III IDH1,2 mutant astrocytoma patients in the Phase IIa trial for NEO100 significantly expands the target patient population. This strategic enrollment change is projected to expedite the trial process, with a readout for Phase II studies potentially delivered by the end of 2024, advancing the original timeline by a full year.
- Initiation and Progress of NEO100 Clinical Trial for Malignant Skull-Based Meningioma: NeOnc launched a Phase IIa trial (NEO 100-02) in July 2023 for intranasal NEO100 in patients with malignant skull-based meningioma. This new indication addresses a patient population with limited effective treatment options and difficult-to-access tumors, representing a potential new market opportunity for NEO100.
- Advancement of NEO212 into Phase I/II Clinical Trials for Primary and Secondary Brain Tumors: The company's second lead product, NEO212, began a Phase I/II trial in the fourth quarter of 2023. This trial administers oral NEO212 to patients with primary brain tumors (malignant gliomas) and secondary brain tumors (brain metastases), representing a new drug candidate entering human testing with the potential to address a broad range of intracranial malignancies.
- Expansion of NEO100 into Parkinson's Disease as a Drug Delivery Vehicle: NeOnc is planning a Phase I clinical trial for intranasal NEO100 mixed with levodopa (L-DOPA) for patients with Parkinson's disease. This initiative expands NEO100's potential application beyond oncology into a new therapeutic area, offering a distinct pathway for future revenue generation if successful.
AI Analysis | Feedback
null
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| NeOnc Technologies Earnings Notes | 12/16/2025 | |
| NeOnc Technologies Stock Dropped 13% - Have You Assessed the Risk | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 12.02 |
| Mkt Cap | 2.6 |
| Rev LTM | 2 |
| Op Inc LTM | -203 |
| FCF LTM | -134 |
| FCF 3Y Avg | -127 |
| CFO LTM | -129 |
| CFO 3Y Avg | -110 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | -43.2% |
| Rev Chg 3Y Avg | 11.3% |
| Rev Chg Q | -40.7% |
| QoQ Delta Rev Chg LTM | -39.0% |
| Op Inc Chg LTM | 4.5% |
| Op Inc Chg 3Y Avg | 0.6% |
| Op Mgn LTM | -7,605.0% |
| Op Mgn 3Y Avg | -9,371.8% |
| QoQ Delta Op Mgn LTM | 5.1% |
| CFO/Rev LTM | -6,106.4% |
| CFO/Rev 3Y Avg | -10,711.0% |
| FCF/Rev LTM | -6,574.7% |
| FCF/Rev 3Y Avg | -11,114.6% |
Price Behavior
Price Behavior
| Market Price | $3.50 | |
| Market Cap ($ Bil) | 0.1 | |
| First Trading Date | 03/26/2025 | |
| Distance from 52W High | -71.1% | |
| 50 Days | 200 Days | |
| DMA Price | $4.21 | $7.71 |
| DMA Trend | down | down |
| Distance from DMA | -16.9% | -54.6% |
| 3M | 1YR | |
| Volatility | 70.1% | 99.9% |
| Downside Capture | 107.69 | 208.30 |
| Upside Capture | -104.04 | 124.72 |
| Correlation (SPY) | -4.4% | 20.3% |
NTHI Betas & Captures as of 7/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | -0.12 | 0.25 | 0.11 | 0.70 | 1.68 | -0.07 |
| Up Beta | 3.17 | -0.04 | 1.11 | 1.14 | 0.06 | -0.58 |
| Down Beta | -0.20 | 0.75 | 1.01 | 1.50 | 2.86 | 0.12 |
| Up Capture | -271% | -71% | -83% | -51% | 165% | 6% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 8 | 17 | 26 | 50 | 114 | 151 |
| Down Capture | 95% | 102% | -0% | 127% | 157% | 94% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 11 | 23 | 34 | 72 | 133 | 179 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NTHI | |
|---|---|---|---|---|
| NTHI | -29.4% | 99.6% | 0.10 | - |
| Sector ETF (XLV) | 28.7% | 15.5% | 1.42 | 10.7% |
| Equity (SPY) | 23.3% | 12.8% | 1.36 | 20.3% |
| Gold (GLD) | 28.5% | 28.4% | 0.87 | 11.9% |
| Commodities (DBC) | 32.9% | 19.8% | 1.32 | -5.2% |
| Real Estate (VNQ) | 14.2% | 13.8% | 0.72 | 5.2% |
| Bitcoin (BTCUSD) | -43.7% | 43.0% | -1.21 | 15.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NTHI | |
|---|---|---|---|---|
| NTHI | -23.4% | 133.5% | -0.13 | - |
| Sector ETF (XLV) | 6.2% | 15.0% | 0.23 | -4.6% |
| Equity (SPY) | 13.5% | 17.2% | 0.61 | -2.0% |
| Gold (GLD) | 18.6% | 18.6% | 0.81 | 4.8% |
| Commodities (DBC) | 8.2% | 19.6% | 0.31 | -7.2% |
| Real Estate (VNQ) | 2.3% | 18.9% | 0.02 | -6.4% |
| Bitcoin (BTCUSD) | 9.0% | 53.0% | 0.36 | 14.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with NTHI | |
|---|---|---|---|---|
| NTHI | -12.5% | 133.5% | -0.13 | - |
| Sector ETF (XLV) | 10.1% | 16.6% | 0.49 | -4.6% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | -2.0% |
| Gold (GLD) | 12.1% | 16.2% | 0.61 | 4.8% |
| Commodities (DBC) | 7.4% | 18.0% | 0.33 | -7.2% |
| Real Estate (VNQ) | 4.8% | 20.7% | 0.20 | -6.4% |
| Bitcoin (BTCUSD) | 58.4% | 66.2% | 0.98 | 14.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 7/15/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/18/2026 | 2.6% | -3.7% | -9.9% |
| 11/14/2025 | -12.3% | -35.5% | -13.8% |
| 8/22/2025 | -0.4% | 27.4% | 104.1% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 2.6% | 27.4% | 104.1% |
| Median Negative | -6.4% | -19.6% | -11.8% |
| Max Positive | 2.6% | 27.4% | 104.1% |
| Max Negative | -12.3% | -35.5% | -13.8% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/18/2026 | 2.6% | -3.7% | -9.9% |
| 11/14/2025 | -12.3% | -35.5% | -13.8% |
| 8/22/2025 | -0.4% | 27.4% | 104.1% |
| SUMMARY STATS | |||
| # Positive | 1 | 1 | 1 |
| # Negative | 2 | 2 | 2 |
| Median Positive | 2.6% | 27.4% | 104.1% |
| Median Negative | -6.4% | -19.6% | -11.8% |
| Max Positive | 2.6% | 27.4% | 104.1% |
| Max Negative | -12.3% | -35.5% | -13.8% |
Recent Forward Guidance
Updated 7/27/2026Latest: Q1 2026 Earnings Reported 5/18/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Operational Runway | 2,026 | ||||||
Prior: Q3 2025 Earnings Reported 11/14/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Quazar Investment Funding | 50.00 Mil | 0 | Affirmed | Guidance: 50.00 Mil for 2025 | |||
Insider Activity
Updated 7/13/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Heshmatpour, Amir F | President | Direct | Buy | 5042026 | 4.16 | 10,000 | 41,592 | 12,777,062 | Form |
| 2 | Heshmatpour, Amir F | President | Direct | Buy | 4282026 | 4.52 | 10,000 | 45,180 | 13,834,116 | Form |
| 3 | Heshmatpour, Amir F | President | Direct | Buy | 4232026 | 4.90 | 10,000 | 49,000 | 14,954,800 | Form |
| 4 | Suh,, David JR | Chief Accounting Officer | Direct | Buy | 4132026 | 5.00 | 200 | 1,000 | 559,330 | Form |
| 5 | Heshmatpour, Amir F | President | Direct | Buy | 4092026 | 5.19 | 5,000 | 25,950 | 15,736,080 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Heshmatpour, Amir F | President | Direct | Buy | 5042026 | 4.16 | 10,000 | 41,592 | 12,777,062 | Form |
| 2 | Heshmatpour, Amir F | President | Direct | Buy | 4282026 | 4.52 | 10,000 | 45,180 | 13,834,116 | Form |
| 3 | Heshmatpour, Amir F | President | Direct | Buy | 4232026 | 4.90 | 10,000 | 49,000 | 14,954,800 | Form |
| 4 | Suh,, David JR | Chief Accounting Officer | Direct | Buy | 4132026 | 5.00 | 200 | 1,000 | 559,330 | Form |
| 5 | Heshmatpour, Amir F | President | Direct | Buy | 4092026 | 5.19 | 5,000 | 25,950 | 15,736,080 | Form |
| 6 | Heshmatpour, Amir F | President | Direct | Buy | 4092026 | 5.61 | 10,000 | 56,050 | 16,966,335 | Form |
| 7 | Heshmatpour, Amir F | President | Direct | Buy | 4062026 | 6.32 | 5,000 | 31,600 | 19,067,440 | Form |
| 8 | Heshmatpour, Amir F | President | Direct | Buy | 4062026 | 6.09 | 20,000 | 121,798 | 18,342,779 | Form |
| 9 | Heshmatpour, Amir F | President | Direct | Buy | 11242025 | 6.51 | 6,000 | 39,060 | 19,477,920 | Form |
| 10 | Heshmatpour, Amir F | President | Direct | Buy | 11242025 | 5.98 | 20,000 | 119,600 | 17,832,360 | Form |
| 11 | Heshmatpour, Amir F | President | Direct | Buy | 11242025 | 6.50 | 4,000 | 26,000 | 19,409,000 | Form |
| 12 | Neman-Ebrahim, Yousha | Chief Clinical Officer | Direct | Buy | 11242025 | 6.69 | 1,100 | 7,359 | 898,199 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 8/8/2026